
Bioorganic and Medicinal Chemistry p. 3490 - 3498 (2015)
Update date:2022-08-05
Topics:
Flesch, Daniel
Gabler, Matthias
Lill, Andreas
Gomez, Roberto Carrasco
Steri, Ramona
Schneider, Gisbert
Stark, Holger
Schubert-Zsilavecz, Manfred
Merk, Daniel
Abstract The ligand activated transcription factor farnesoid X receptor (FXR) is a crucial regulator of several metabolic and inflammatory pathways and its activation by agonistic ligands seems a valuable therapeutic approach for many disorders. Most known non-steroidal FXR agonists however, have limitations that hinder their clinical development and novel FXR ligands are required. Evaluation of the co-crystal structures of the widely used FXR agonist GW4064 and related compounds in complex with the FXR ligand binding domain indicated that their disubstituted isoxazole moiety is especially relevant for FXR activation. By investigation of GW4064-fragments missing the aromatic tail, we discovered a highly potent and soluble partial FXR agonist (14, ST-1892) as well as a fluorescent FXR ligand (15) as potential pharmacological tool.
View MoreContact:0086-357-6662688
Address:Zhaocheng town, Hongtong County, Linfen City, Shanxi Province
Contact:+86-10-83993285
Address:Rm.1708, Haobai Tower, Building 6, No.50, North Road, West Third Ring, Haidian District, Beijing, China
Contact:
Address:ROOM 1715, No#345 Jin Xiang Road, Pudong District
He Bei Shun Er Chemical Co., LTD.
Contact:86-0311-86996932/86860168
Address:No 18,North street
Contact:86-28-61993785
Address:No.70-13-21, North Section, Erhuan
Doi:10.1021/ja00238a067
(1987)Doi:10.1021/np0505521
(2006)Doi:10.1016/j.bmcl.2006.03.023
(2006)2
Doi:10.1016/S0022-328X(00)99284-2
(1983)Doi:10.1039/c39860000249
(1986)Doi:10.1021/jm00375a013
(1984)